Soleno Therapeutics (NASDAQ:SLNO) Rating Lowered to Hold at Robert W. Baird

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by investment analysts at Robert W. Baird from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently commented on SLNO. Wall Street Zen cut shares of Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. HC Wainwright reduced their price target on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Lifesci Capital cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Oppenheimer reduced their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating for the company in a report on Wednesday, March 18th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $93.90.

Soleno Therapeutics Trading Up 0.2%

NASDAQ:SLNO opened at $52.35 on Monday. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 227.62 and a beta of -2.81. The firm has a fifty day simple moving average of $38.17 and a two-hundred day simple moving average of $47.80. Soleno Therapeutics has a 12 month low of $29.43 and a 12 month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Analysts expect that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics during the second quarter valued at about $25,000. Danske Bank A S acquired a new position in shares of Soleno Therapeutics during the third quarter valued at about $27,000. Global Retirement Partners LLC grew its holdings in shares of Soleno Therapeutics by 519.0% during the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after buying an additional 519 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Soleno Therapeutics during the third quarter valued at about $37,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Soleno Therapeutics during the fourth quarter valued at about $38,000. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for about $2.9B, offering $53.00 per share in cash (a meaningful premium to recent trade); the deal provides a near‑term liquidity event and floor for shareholder value. Neurocrine to Buy Soleno for $2.9 Billion
• Positive Sentiment: Market commentary and coverage noted the $53/share offer and framed it as a strategic fit for Neurocrine’s rare‑disease/endocrinology push, supporting near‑term upside to the transaction price if the deal closes. Neurocrine Biosciences to acquire Soleno Therapeutics
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for its Prader‑Willi treatment as Neurocrine sharpens focus on the U.S. market — a programmatic change that reduces near‑term EU regulatory exposure but removes a potential international revenue opportunity. Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
• Negative Sentiment: Several sell‑side firms downgraded or cut price targets (Cantor Fitzgerald, Wolfe Research, Lifesci; TD Cowen cut its target to $53 from $85) — analyst caution could pressure sentiment and constrain upside beyond the deal price. Cantor Fitzgerald Downgrades Soleno Therapeutics
• Negative Sentiment: Multiple securities class‑action lawsuits, and a flurry of law‑firm notices seeking lead plaintiffs, allege disclosures issues tied to the DCCR (VYKAT XR) program; several firms are investigating the fairness of the Neurocrine deal and potential fiduciary claims — these legal risks can create deal uncertainty, potential remediation costs, and timeline delays. Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit
• Negative Sentiment: Investor‑rights and M&A litigation firms have launched investigations into whether Soleno’s board obtained a fair price and whether prior disclosures misstated drug risks — these actions raise the chance of post‑deal litigation or negotiated adjustments. Halper Sadeh investigation into sale price

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.